Drug recall · July 29, 2026
Dabigatran etexilate Capsules recall
Why: Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.
- Lots / codes
Lot: 25141707, Exp 4/30/2027.
- Quantity
- 1,753 cartons
- Company
- Ascend Laboratories, LLC, Bedminster, NJ
- Distribution
- USA Nationwide
- Initiated
- June 30, 2026 · Voluntary: Firm initiated
- Classified
- August 4, 2026
- Reported
- July 29, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Dabigatran etexilate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.